Winter 2001

Official publication of SOHNA

Prescription for Influenza

The Healing Crisis

Pediatrics

JOURNAL OF

BIOMEDICAL THERAPYIntegrating

Homotoxicology

and Mainstream

Medicine

JOUR

NAL

OF B

IOME

DICA

L TH

ERAP

Y

Inside SOHNA 3

Homotoxicology In Brief 4

Practical Protocols• Viruses 6• Influenza 6• Euphorbium 7

Medical Abstracts• Antihomotoxic treatment

of agitation, with andwithout fever, in children 8

Medical Summaries 12

In Your PracticeThe Healing Crisis 14

Pediatric ColumnUse of Viburcol 15

SUMMARY

Since this is an international publication, names and availabilityof the products mentioned in this journal may vary from onecountry to another.

MEDICAL EDITOR/WRITER: Jo Serrentino

MANAGING EDITOR: Virginie Dionne-Bourassa

PROOFREADING: Andy Moss

GRAPHIC DESIGN: Phaneuf Design Graphique

CIRCULATION: 10,000

Made and printed in Canada

The first issue of SOHNA’S JOURNAL OF BIOMEDICAL THERAPY has come and

gone and we are thankful to our readers for their comments. Useful information came

from extrapolating answers from the survey on the back cover of the magazine, and

future topics and themes relevant to our readers are guaranteed.

Comments came from several countries thanks to Heel offices around the world that

helped route the filled-in surveys. Interestingly, the answers were consistent. Readers

“gained specific information,” and wished to receive future copies. The amount of time

spent reading was split right down the middle between 20 minutes and 60 minutes,

more or less reaching our projected goal of 45 minutes.

There were many suggestions for

topics, ranging from neoplasms to

more veterinary medicine, and a defi-

nite penchant for sports medicine. All

in all, we were very pleased with the

results of the survey as the ultimate

purpose of the magazine is to share

information. We will try our best to

fulfill all requests to bring you a publi-

cation you can count on for filling

your therapeutic information needs.

Thank you to all those individuals

who took the time to answer and

send in the survey, we appreciate your

cooperation and commitment.

Virginie Dionne-Bourassa

Managing Editor

Inside SOHNA

3

P.O. Box 2698

Edgewood,NM

87015

1-800-963-6226

SOHNASociety of Homotoxicology

of North America

We are proud to announce that Dr. BruceShelton is now the official President ofSOHNA. You will have the chance to meetBruce in this same column in April 2001 inthe next issue. Dr. Shelton is also the MedicalDirector for Heel Inc. He assumed this posi-tion last January 1, 2001. Heel Inc. requestedhim to be their Medical Director because ofhis great regard to the world of Homeopathyand Homotoxicology.

Dr. Shelton received his medical degree from New York Medical College in 1971 andcompleted his internship/family practice residency at the Good Samaritan Hospital inPhoenix, Arizona in 1974. He is a licensedHomeopathic M.D. and practices in Phoenix.Dr. Shelton’s professional affiliations includeThe American Medical Association, TheArizona Medical Association, The AmericanAcademy of Family Physicians, and The Arizona Homeopathic and Integrative MedicalAssociation, and SOHNA will gladly benefit from having him aboard!

Homo

toxico

logy IN BRIEF

4

HUMORAL PHASES MATRIX PHASESORGAN SYSTEM EXCRETION PHASES INFLAMMATION PHASES DEPOSITION PHASES

Skin and Adnexae Acute mycosis, erysipelas Warts• Skin Exanthema, episodes Acne, herpes simplex, Keratoderma, naevi,

of sweating, desquamation diaper rash, varicella pruritus

• Hair and nails Folliculitis Toxin storage• Subcutis Sweat-gland disorder Phlegmon, abscess Atheroma, obesity

Peripheral and Central Neurasthenia, malaise, exhaustion, Headaches, dizziness, CerebrosclerosisNervous System difficulty concentrating, lack encephalitis, meningitis

of strength/energy• Peripheral nerves Neurasthenia Neuritis, lumbago,

sciatica, neuralgia

Sensory System• Eyes Tears Conjunctivitis, Hordeolum, chalazion,

blepharitis, keratitis vitreous opacity• Ears Otorrhoea, cerumen Otitis media, otitis externa Otosclerosis, cholesteatoma, otoliths• Sense of smell

Locomotor System• Bone/cartilage Bone disorder, cartilage disorder Osteomyelitis Exostosis, heel spur, osteoma• Spinal column/joints Joint pains, arthropathy, Rheumatoid arthritis, shoulder-arm Periarthritis, calcarea

serous discharge syndrome, synovitis, periarthritis, epicondylitis• Connective tissue Ligament disorder Fibrositis, tendovaginitis Gout, fibrosis, myogelosis• Muscles Back disorder Myalgia, myositis Myogelosis

Respiratory Tract Infection Fever, influenza Susceptibility to infections• Throat Epistaxis, rhinorrhea, Tonsillitis, sore throat, laryngitis, Chronic rhinitis, candidiasis, tonsillar

Nose cerumen, hypersalivation rhino-pharyngitis, otitis media, otitis externa, blockages, chronic sinusitis, tonsillar Ears sinusitis, tracheitis, herpes infection hypertrophy, abscess, adenoids

• Bronchi Cough, expectoration Bronchitis Bronchopneumonia• Lungs Dyspnea Pneumonia Silicosis, smoker’s lung

Cardiovascular System Circulatory disorder• Heart Functional heart complaint Endocarditis, pericarditis, Coronary heart disease

myocarditis• Arteries Hypotensive dysregulation Endarteritis Peripheral vascular disease I,

arteriosclerosis, embolism• Veins Orthostatic syndrome Phlebitis Edema, thrombosis, thrombophlebitis• Lymph vessels Lymph flow Lymphadenitis Edema, lymph-node swelling

Gastrointestinal System• Teeth-mouth-jaws Salivation Glossitis, pulpitis, osteitis of Granuloma

the jaw, periodontitis• Esophagus Heartburn Esophagitis Achalasia• Stomach Nausea, vomiting, dyspepsia Gastroenteritis, gastritis Hyperplastic gastritis• Duodenum Gastroduodenitis• Small intestine Diarrhea Ileitis, jejunitis• Large intestine Bloating, flatulence, diarrhea Enteritis, colitis Melanosis coli, constipation,

candidiasis, polyposis coli• Liver-bile Bile Cholangitis, cholecystitis, hepatitis Cholecystolithiasis, fatty liver• Pancreas (excretory) Pancreatitis Siderosis

Urogenital System Urinary tract infection Bladder stones• Kidneys Polyuria Pyelonephritis Kidney stones• Bladder Bladder disorder, irritable bladder Cystitis, dysuria Bladder stones• Sex organs Leuorrhea, menstruation, Dysmenorrhea, prostatitis, orchitis, Prostatic hyperplasia, myoma,

mamillary secretion adnexitis, vaginitis and vulvo-vaginitis, ovarian cyst, endometriosiscandidiasis of the vulva/vagina

Blood• Erythrocytes Bleeding, reticulocytosis Polycythaemia• Leucocytes Leucocyte migration Leucocytosis, suppuration Abscess formation• Platelets Thrombocytosis

Lymph System Lymphoedema Lymphangitis, tonsillitis, lymphadenitis Lymph-node swelling

Metabolism Electrolyte shift Lipid metabolism disturbance Gout, obesity, hyperlipidaemia

Hormone System Endocrine disturbances• Hypothalamus/Pituitary Pituitary adenoma• Thyroid Globus sensation, hyperthyroidism Thyroiditis Goiter, adenoma• Pancreas (endocrine) Acute pancreatitis• Adrenals Catecholamine secretion (stress)

Immune System Susceptibility to infection Weak immune system, acute infection Weak reactions

Alteration* Reaction* Fixation*Psyche Functional psychological Reactive depressive syndromes, Psychosomatic manifestation, neuroses,

turbance, "nervousness" hyperkinetic syndrome phobias, neurotic depression

The six-phase table is a field matrix reflecting medical experience based on careful observation and empirical learning.It is a phase-by-phase arrangement of disorders with no direct relationship between them. No causal pathogenetic link between disorders can be inferred.The structure of the table makes it suitable for developing a prediction system giving a better assessment of the possibilities for a vicariation effect. Revised: July 2000.

T H E H O M O T O X I C O S I S ( T H E S I X - P H A S E T A B L E )

BI

OL

OG

IC

AL

DI

VI

SI

ON

The table of homotoxicosis is an extensive classification of human diseases relative to the embryonic layer fromwhich the affected tissue originates and of how the organism will react at that particular point. When the cli-nical picture at the time of consultation is applied to the table, the progress of the disease can be mapped outwith the indication of the tissue specifically affected. By relating the patient’s past diseases to the table, thephysician can get a clear picture of that patient’s disease process.

USE OF THE TABLE OF HOMOTOXICOSIS

Homo

toxico

logyIN BRIEF

5

MATRIX PHASES CELLULAR PHASESImpregnation Phases DEGENERATION PHASES DEDIFFERENTIATION PHASES

AllergyContact eczema, psoriasis, seborrheic Decubitus ulcer, rosacea Basaloma, melanoma,eczema,chronic mycosis, urticaria, carcinomaneurodermatitis, pemphigus, lichen ruberOnychomycosis AlopeciaCellulitis Lupus erythematosus, scleroderma, Lipoma

vitiligo, cutaneous lymphoma

Convulsions, sleep disturbances, Parkinson’s disease, epilepsy, cerebral ischemia, Neuroma, glioma, gliosarcoma, migraine, TIA, dyslexia disseminated encephalomyelitis, dementia, meningioma

Alzheimer’s diseaseImpulse conduction disturbance, chronic Polyneuropathy, neurodystrophy Neurofibromatosisneuralgia, e.g. trigeminal neuralgia

Chronic conjunctivitis, Sicca syndrome, cataract, retinitis pigmentosa, Blindness, malignant tumoruveitis, iridocyclitis glaucoma, retinal detachment, macular degenerationTinnitus, labyrinthine vertigo Impairment of hearing Deafness, neoplasms

Anosmia

Soft-tissue rheumatism Spondylosis SarcomasOsteoporosis, bone cysts, osteomalacia Chondroma

Chondropathy, chronic rheumatoid Degenerative rheumatism, generalized osteoarthritis, Osteosarcomaarthritis, cervicobrachial syndrome disk prolapse, Bekhterev’s diseaseFibromyalgia syndrome Lower-leg ulcer Fibroma, fibrosarcomaSoft-tissue rheumatism Muscular atrophy Myoma, myosarcoma

AllergyAllergic rhinitis, chronic rhinitis, Atrophic rhinitis, ozena, crypts Leuoplakia, oral and lingual aphthae, chronic tonsillitis, dizziness carcinoma, lymphoma

Chronic (obstructive) bronchitis, asthma Atelectasis, bronchiectasia, status asthmaticus Bronchial carcinoma, mesotheliomaTuberculosis, alveolitis Emphysema, pulmonary fibrosis Lung cancer

Heart failure, hypertensive heart disease, Heart failure, cardiac arrhythmia, coronary heart Endothelioma, rhabdomyosarcomaextrasystoles, angina pectoris disease, myocardial infarction, myocardiopathyHypertension, essential, hypo-tension, Atrial fibrillation, atrial flutter, peripheral Endothelioma, peripheral chronic, peripheral vascular disease II vascular disease III, arteriosclerosis vascular disease IVVenous valve insufficiency Varices, hemorrhoids, crural ulcer EndotheliomaLymphatism Elephantiasis Lymphangiosarcoma, lymphoma

AllergyCaries Periodontosis Leuoplakia, lingual and mucosal carcinoma

Cardiac insufficiency Metaplasia Esophageal cancerChronic gastritis Atrophic gastritis, gastric ulcer, peptic ulcer Stomach cancer

Duodenal ulcerMalabsorption, sprue MalabsorptionIrritable colon, ulcerative colitis, Diverticulosis Colon cancerCrohn’s diseaseLiver function disturbance Liver cirrhosis Hepatocellular carcinoma, cholangiomaChronic pancreatitis Excretory pancreatic failure Pancreatic cancer

IncontinenceNephrotic syndrome, chronic renal failure Chronic renal failure, renal atrophy Kidney cancer, hypernephromaDysuria, chronic urinary tract infection Bladder cancer, bladder papillomaChronic prostatitis Impotence, testicular atrophy, Peyronie’s disease, Testicular cancer, prostate cancer, uterine

atrophic vaginitis, sterility cancer, ovarian cancer, cervical cancer

Disturbed fluidity balance, disturbed viscosity Coagulation disturbanceAnemiaLeuocytopenia Leukemia

Aggregation disturbance Thrombocytopenia

Insufficiency of the lymph system Fibrosis Lymphoma, Hodgkin-/non-Hodgkin lymphoma

Metabolic syndrome Iron-deficiency anemia, diabetes mellitus Slow reactions

Menopausal symptomsAcromegaly

Hyperthyroidism, autoimmune thyroiditis Hypothyroidism, nodular goiter Thyroid cancerGlucose intolerance Diabetes mellitus, pancreatic fibrosis Insulinoma, glucagonoma Addison’s disease, Cushing’s disease Adrenal atrophy Adrenal cancer

Autoimmune disease, immunodeficiency, AIDS Slow reactionschronic infections

Chronic forms* Deficits* Decoupling*Endogenous depression, psychosis, Schizophrenic defective states, mental deficiency Mania, catatoniaanxiety neurosis, organic psychosyndrome

*Phase nomenclature in psychology.

T H E H O M O T O X I C O S I S ( T H E S I X - P H A S E T A B L E )

BI

OL

OG

IC

AL

DI

VI

SI

ON

@For t

he

ele

ctr

on

ic v

ers

ion

of

this

tab

le v

isit

ou

r lib

rary

se

ctio

n a

tw

ww

.he

el.c

a

More often than not, more than one remedy is used in homotoxicological treatment. Each remedy may be directed at a different level of the disease, and thus appear at different places in the table.

It is important to understand that the indications contained in the table cells are not necessarily related in cause or pathology.

The table is designed to present possible vicariations and their symptomatic development. The indicationsare arranged in ascending order; starting with the least complicated and ending with the most complicated.

The yellow shading used in the table below represents the possible uses of ENGYSTOL. The lightly shaded areas represent the clinical application of ENGYSTOL while the heavily shaded area of the table illus-trates the treatment of choice for an underlying disease process.

VIRUSESPractic

al PROTOCOLS

6

The antihomotoxic remedy of choice for viral infections is ENGYSTOL.

The name of the main ingredient, VINCETOXICUM, means to “vanquish toxins”. This is in fact

ENGYSTOL’s mode of action, to act on the deep-seated biochemical nature of the immune attack against

the virus, through enzymatic action and neutralization of associated toxins. It defuses the viral siege rather

than directly attacking the virus in a virucidal capacity. Together with the sulphur attenuations in the for-

mula, Engystol mediates the sulphide enzymes. This results in a stimulation of immune function and a deep

detoxication.

APPLICATIONS OF ENGYSTOL:Engystol has a wide spectrum of application:

• VIRAL INFECTIONS

• BACTERIAL INFECTIONS

• RESPIRATORY CONDITIONS

• ALL TYPES OF ALLERGIES

• DERMATOSIS

Specifically, ENGYSTOL exerts a generally lowering action on high

homotoxin levels, especially after therapeutic damage with the

presence of impregnation and possibly also degeneration phases,

especially of viral diseases.

ENGYSTOL activates the body’s own non-specific defenses, particularly in vague feverish infections, and

for influenza, and viral infections of all kinds, as well as after vaccination.

ENGYSTOL is particularly attractive in protocols for respiratory conditions; such as, bronchitis, bronchiec-

tasis, pertussis, pneumonia, and asthma.

INJECTION PRESCRIPTION FOR INFLUENZAENGYSTOL

1 ampoule, 3 times per week: First injection can be given i.v.

Adding TRAUMEEL to the i.v. injection will make the patient feel better and be able to rest upon return home.

ORAL PRESCRIPTION FOR INFLUENZA - treatment and symptomsENGYSTOL: 1 ampoule orally, 3 times per week for one week.

GRIPP-HEEL: 1 tablet 3-5 times per day for the first 3 days, then reduce to 3 times per day for 7 days.

TRAUMEEL: 1 ampoule per day orally, or 1 tablet tid.

RESPIRATORY AILMENTS which occur, either, as secondary conditions from viral infections such as

influenza, or as primary cause can be treated with the same protocol with the addition of MUCOSA

COMPOSITUM.

INFLUENZA

7

PRESCRIPTION FOR RESPIRATORY CONDITIONENGYSTOL: 1 ampoule 3 times per week; for 1-2 weeks.

MUCOSA COMPOSITUM: 1 ampoule per day for 2 days; then 1 ampoule 3 times per week for 2 weeks.

Review the case at this time, continue for another week if necessary.

TRAUMEEL: 1 ampoule per day for 5-7 days, or 1 tablet 3-5 times per day for 7-10 days.

Physicians can give an initial i.v. injection of the three remedies (Engystol, Mucosa compositum, and

Traumeel).

Practic

alPROTOCOLS

Components of Euphorbium compositum nasal spray

Cytokine IFN-γ TNF-α IL-10

Donor A B C A B C A B C

Euphorbium D4 47% 50% 13% 5% 3% -18% 0% -15% 1%

Euphorbium D6 47% 33% -52% 3% 4% -8% 31% -8% -8%

Euphorbium D8 7% 34% -27% -1% 15% 0% 11% -13% -23%

In vitro studies on whole blood cultures have demonstrated that each

of the ingredients in EUPHORBIUM Compositum Nasal Spray

influence, in varying degree, the release of certain immune modulators.

For example, the release of interferon (IFN-γ) and interleukin-10

(IL-10) were strongly affected by the ingredients of Euphorbium

Compositum Nasal Spray. The release of tumor necrosis factor

(TNF-α) was marginally affected by the ingredients of Euphorbium

Compositum Nasal Spray. (See values in chart).

In Vitro studies using human cell cultures indicate that the effectiveness

of Euphorbium Compositum Nasal Spray may also be due to direct

virustatic effects. Compared to normal saline solution, dilutions of

Euphorbium Compositum Nasal Spray were found to inhibit both the

influenza A virus and sinorespiratory infections.

EUPHORBIUM COMPOSITUM®

FOUND TO INHIBIT VIRUSES RESPONSIBLE FOR COLD AND FLU...

Medic

al ABSTRACTS

8

In line with the objectives of this post-marketing clinical study, no conditionswere imposed on the participating doc-tors as regards to diagnosis and the ad-ministration of treatment or the natureand extent of monitoring investiga-tions. The maximal duration of obser-vation was set at 4 weeks per patient.Data on the patients and treatments,which were collected in a preliminaryexamination and a final examinationand in one or two optional intermedi-ate examinations, were recorded onindividual case report forms. In addi-tion to demographic data/vital parame-ters, the documented informationincluded the nature of the underlyingdisease and details of the dosage ofViburcol, any other medicinal or non-

medicinal therapies, and the nature ofany accompanying illnesses.

The therapeutic efficacy of the treat-ment was evaluated on the basis of thefollowing parameters:

• The change in the severity of three,individually defined, principal symp-toms (scale: absent = 1, mild = 2, mod-erate = 3, severe = 4, very severe = 5)

• The length of time to the firstimprovement in the symptoms

• An overall assessment of the outcomeof treatment (scale: very good, good,moderate, unsuccessful, worse).

The tolerability of Viburcol was ascer-tained on the basis of the followingparameters:

• Adverse drug reactions

• An overall assessment of tolerability(scale: very good, good, moderate,poor)

• Patient compliance (scale: very good,good, moderate, poor).

The data were subjected to statisticalevaluation using exploratory methods;absolute and relative frequencies andthe associated 95% confidence intervalswere presented. The postmarketingclinical study was carried out in accor-dance with the “Recommendations forthe planning, performance, and evalua-tion of postmarketing clinical studies”(Bundesanzeiger Federal Gazette) No.229 of 04. 12.98).

Agitation, nervousness, difficulty ingetting to sleep and sleeping through,and disturbances of general well-beingin children are often the manifestationof a diagnosable underlying disease.These symptoms can be produced byinfections such as otitis media, bron-chitis, pharyngitis, and urinary tractinfections in particular. The othermain possible causes are odontoneural-gia, tooth-eruption problems, and painresulting from stomach cramps andcolic caused by wind. Since infectionsare frequently accompanied by fever,one must consider whether or notantipyretic/analgesic therapy is appro-priate. The main agents employed forthis in conventional medicine areaspirin, paracetamol, and NSAIDs(nonsteroidal anti-inflammatory drugs),but their use is controversial. Firstlybecause of the possibility of unwanted

side effects and secondly because of theview that fever can fulfil an importantfunction in the body by conditioningand stimulating the immune system –provided that a tolerable range is notexceeded. Nor should one underesti-mate the widespread attitude of expec-tancy on the part of the parents of thesick child, who believe that fevershould be reduced and should be treated medicinally and who thus contribute to the high level of use ofthese substances.

The primary objective of administer-ing, say, paracetamol as an antipyret-ic/analgesic is symptomatic therapy toreduce the health problems caused by the infection and thus help the sick child feel better more quickly.However, the possibility of side effectsand the impairment of the immunefunctions raises the question of

whether there are not perhaps othertreatment options which produce com-parable therapeutic results without theabove-mentioned risks.

There is a homeopathic remedy available for this purpose: Viburcolsuppositories for children and babies(manufactured by Biologische Heil-mittel Heel GmbH, Baden Baden/Germany), the product’s primary usebeing in the treatment of trivial infec-tions and of agitation with or withoutfever (Table 1). As an earlier postmar-keting clinical study showed, Viburcolis employed predominantly in infec-tious diseases, nervous agitation andpain. A postmarketing clinical studyundertaken in 1999 collected data on the efficacy and tolerability ofViburcol in the treatment of agitationwith and without fever under condi-tions of routine use.

ANTIHOMOTOXIC TREATMENT OFAGITATION, WITH AND WITHOUT

FEVER, IN CHILDRENRESULTS OF A POSTMARKETING CLINICAL STUDY

In a drug monitoring data were ascertained on the efficacy and tolerance of the homeopathic remedy Viburcol. Children and infantswere treated, suffering from nervousness with or without fever. Infections (particularly respiratory tract infections), general nervous-ness, toothing complaints and stomach ache were primary underlying diseases.

The efficacy of the treatment was assessed by the participating pediatricians as “very good” or “good” in over 90% of the cases. The mean of the intensity of clinical main symptoms was reduced from 3.2 at treatment start to 1.3 at the end of thetreatment (5-point scale). A first global improvement of the diseases was observed in approximately 80% of the cases in the first treatment week for the total patient population. The assessment of the tolerability of the remedy was positive.

Keywords: Children, drug monitoring, fever, homeopathy, nervousness, Viburcol.

Rainer Gottwald, Michael Weiser Reprinted from Biologische Medizin, Vol. 28 No. 6, 1999, pp. 308-312

Sum

mar

y

INTRODUCTION

METHODS

9

Medic

alABSTRACTS

The 36 pediatricians in this postmar-keting clinical study treated a total of321 children with Viburcol. Analysisof the demographic data shows thatthe patients included in the study wereprimarily infants. The patients’ meanage was 1.3 years, the range being 11days to 12 years. The percentages ofboys and girls were comparable: 52%girls, 45% boys (no information on3%). Before the diagnosis was estab-lished, a general categorization of thepatients was undertaken according tothe basic symptom: patients with agita-tion with fever (group A), patients withagitation without fever (group B). Thespecified diagnoses showed that in thefebrile group infections predominated,occurring in 87% of cases. In the non-febrile group the commonest diagnosiswas general agitation (34%), followedby tooth-eruption problems (22%),abdominal pain (17%), and infectionsand other diagnoses (both with 13%)(Table 2).

The commonest infections treatedwith Viburcol were reported as: respi-ratory tract infections, influenza, otitismedia, intestinal infections, and uri-nary tract infections. The most com-mon problem treated in those withgeneral agitation was difficulty in get-ting to sleep and sleeping through, withnocturnal screaming and hyperagility.The product was also used to treataccompanying symptoms (agitation)resulting from dermatological com-plaints (including atopic dermatitis,exanthem, and eczema).

To characterize the diagnosed illnessand as a parameter for ascertaining thetherapeutic efficacy of the treatment,three individual principal clinicalsymptoms were identified for eachpatient by the doctors at the start oftreatment. The identified symptoms,with their numerical frequencies, are asfollows: sleep disturbances (27%), pain(19%), fever (14%), agitation (12%),

screaming/screaming fits (7%), sweat-ing (7%), eating and drinking prob-lems (4%), gastrointestinal problems(3%), breathing problems (2%), cough(1%), pruritus (1%), rhinitis (1%), ele-vated temperature (1%), others (1%).

The overall severity and the nature andduration of the illness were to beassessed at the start of the treatment.As regards to the severity and thenature of the illness, the biggest cate-gories in both groups of patients(group A: agitation with fever, groupB: agitation without fever) were“moderate” (A: 66%, B: 58%) and“acute”. (A: 88%, B: 55%). The dura-tion of illness at the start of the studywas 1-3 days in most cases (71%) in group A. 1-3 days was also thebiggest category in group B, thoughless markedly so (41%), as durations of 4-7 days and 1-2 weeks were also relatively common (20% and 26%respectively) (Table 3).

PATIENTS

TREATMENT

The therapeutic efficacy of the treat-ment was ascertained, inter alia, fromthe change in the intensity of individu-ally defined principal clinical symp-toms; the intensity of these symptomsin the total population decreased from3.2 at the start of treatment to 1.3 atthe end of treatment (arithmetic mean,

scale: absent = 1, up to very severe = 5,all symptoms together).

With regards to the intensity of theprincipal symptoms at the start oftreatment, the differences betweengroup A and group B were only slight;there was a tendency to a slightlygreater reduction of symptom intensity

over the course of treatment in group A(Fig. 1). If the four most commonlymentioned principal symptoms areconsidered individually, one finds thatthe biggest decrease in symptom inten-sity was for “fever” (difference betweenpreliminary examination and finalexamination = 2.3), followed by “pain”

THERAPEUTIC EFFICACY

At the start of treatment 46% of thepatients in group A (agitation withfever) were prescribed the regulardosage recommended by the manufac-turer of Viburcol (1 x 1–3 supposito-ries/day) and 12% were prescribed anacute dosage (1 suppository severaltimes daily). A combination of the reg-ular dosage and acute dosage, asrequired, was reported for 42% of thepatients. The corresponding data forpatient group B (agitation withoutfever) were as follows: regular dosage66%, acute dosage 11%, combinedregular and acute dosage 23%. Thecommonest dosage used in the patientsprescribed the regular dosage was 2 x 1suppository/day (46% of cases) (allpatients: 1 x 1 suppository/day = 22%,2 x 1 = 46%, 3 x 1 = 27%, other

dosages = 5%). The mean duration oftreatment was 19 days (median 16days). In group A, the dose waschanged at the first intermediate exam-ination (median 6 days) in 49% ofcases, being reduced in 92% of thesecases and increased in the other 8%; ingroup B the dose was changed in 36%,being reduced in 86% of these casesand increased in 14%.

12% of the patients had an accompa-nying illness at the start of the treat-ment; the commonest accompanyingillnesses were skin diseases, infections,and gastrointestinal complaints. Withregards to the use of additional medici-nal agents or other forms of therapy forthe treatment of the diagnosed under-lying disease at the start of treatment,there were clear differences between the

two groups of patients. Whereas, inpatient group A (agitation with fever),no additional medicinal or other formof therapy was used in 26% of cases,the corresponding figure in patientgroup B (agitation without fever) was66%. However, these differences applyprimarily to the starting situation at thebeginning of treatment. By the 1stintermediate examination 74% of thepatients in group A were also beingtreated solely with Viburcol (group B =80 %). In the cases where patients ingroup A were prescribed accompany-ing therapy with a medicinal agent, thepredominant products were mucolyticsand nasal drops. In group B a widerrange of diseases was treated, so no par-ticular categories stood out in thisrespect.

COMPOSITION OF VIBURCOL AND HOMEOPATHIC PROFILES OF THE INDIVIDUAL CONSTITUENTS.

Constituents/Potency Characteristics/SymptomsChamomilla D1 Inflammation of the respiratory organs. Tooth-eruption problems. Inflammation and spasm of the

digestive organs. Intense pain. Irritability.Belladonna D2 Highly febrile inflammation of the tonsils, respiratory organs, gastrointestinal tract, urogenital

organs, meninges, skin, and joints.Dulcamara D4 Febrile infections. Inflammation of the respiratory organs, gastrointestinal tract, urinary tract, joints,

and skin, triggered by cold and damp.Plantago major D3 Pain in head region. Bed wetting. Diarrhoea. Skin rashes.Pulsatilla D2 Inflammation of the airways and tendency to colds. Inflammation and disturbances of the

digestive organs. Inflammation of the bladder. Inflammation of the middle ear. Measles,mumps, headache. Sleep disturbances, psychological problems. Nervous disturbances, distur-bances of mood.

Calcium carbonicum Hahnemanni D8 Disturbances of calcium metabolism. Chronic disorders of the skin and mucous membranes.

Medic

al ABSTRACTS

10

(difference = 2.1), and “sleep distur-bances” and “agitation” (difference =1.9 in each case) (Fig. 2).

The therapeutic efficacy of the treat-ment was also determined on the basisof the length of time to the first globalimprovement in symptoms. Table 4shows that this occurred within the

first 7 days in over 88% of the patientsin group A (agitation with fever) and inover 71% of the patients in group B(agitation without fever).

The overall assessments of the thera-peutic results by the pediatricians showthat, in both groups, the outcome oftreatment was “good” or “very good” in

over 90% of the cases treated. The pre-scription of accompanying therapy didnot have any decisive influence as far asthe assessments of therapeutic outcomeare concerned: the outcome of treat-ment was also rated as “good” or “verygood” in over 90% of the patientstreated with Viburcol alone (Table 5).

TOLERABILITYThe tolerability of Viburcol was like-wise rated favorably in the majority ofcases, being evaluated as “very good” in92% of patients and “good” in 7%.Tolerability was only rated as “poor” in1 out of the 321 cases; increasingabdominal colic with vomiting wasreported in this patient, who had anunderlying illness of an allergic nature

(allergy to cows’ milk); however, sinceaccompanying medicinal therapy wasused (Symbioflor 1 + 2 in the last 2weeks before the start of the treatment,Pankreaplex and Carbo vegetabilis dur-ing the treatment), assignment to aparticular product – if, indeed, this wasa case of intolerance to a medicinalagent at all – is not possible. Another

adverse drug reaction (navel colic andagitation, in a patient whose underly-ing illness was a febrile infection of theupper respiratory tract) was attributedto overdosage due to a lack of compli-ance. The treating doctors rated patientcompliance as “very good” to “good”in 95% of cases and as “poor” in 0.3%of cases only.

DISCUSSIONThe postmarketing clinical study pre-sented here investigated the range ofuse of Viburcol and also its therapeuticefficacy and tolerability. The patients(children and babies) were divided intoan “agitation with fever” group and an“agitation without fever” group, inaccordance with the indications of theproduct. The commonest diagnosiswas infection (respiratory tract infec-tions in particular), followed by gener-al agitation, tooth-eruption problems,and abdominal pain. In manyinstances antipyretic/analgesic therapy,e.g. with paracetamol, is quickly initi-ated – often at the insistence of the parents. The controversial nature of such treatment (side-effect profile,immunomodulating significance offever) raises the question of therapeuticalternatives for cases in which there isno compelling indication for antipyre-sis or analgesia. Mildly sedative, symp-tomatic treatment is promising here,

especially for diseases that are notamenable to causal therapy. A compar-ative study in children with otitismedia, for example, showed that thespecific symptoms improved morequickly with homeopathic treatmentthan with conventional treatment.

The basic symptoms (agitation with/without fever) in the illnesses treatedwith Viburcol in this postmarketingclinical study predominantly repre-sented acute problems of “moderate”severity which had been present foronly a short time prior to the start oftreatment (< 3 days). The nature of thedocumented principal clinical symp-toms was typical of the diagnoses thatwere made, the commonest symptomsbeing sleep disturbances, pain, fever,and agitation. The intensity of theprincipal symptoms decreased signifi-cantly in both groups of patients as thetreatment progressed. Overall, themean intensity in the total population

fell from 3.2 to 1.3 (scale of 1-5).

In the majority of instances, the firstglobal improvement in symptoms wasseen in the first week of treatment. Therapid reduction of the intensity of thesymptoms is in line with the globalassessments of the therapeutic results,which the treating doctors rated as“very good” or “good” in over 90% ofcases. This efficacy, combined withgood tolerability and compliance,make Viburcol a reliable remedy forthe treatment of children and babieswith agitation with or without fever,resulting from things such as infection(especially respiratory tract infectionsand otitis media), tooth-eruptionproblems, or other forms of pain.

References: See Biologische Medizin, Vol. 28 No. 6, 1999, p. 312.

For the authors: Dr. Michael WeiserGleißlestraße 3477815 BühlGermany

Tabl

e 1

11

Medic

al ABSTRACTS

PERCENTAGE DISTRIBUTION OF PATIENTS ACCORDING TO BASIC SYMPTOMS “AGITATION WITH/WITHOUT FEVER”AND PERCENTAGE IN VARIOUS DIAGNOSIS GROUPS.Diagnosis groups Basic symptoms

Agitation with fever Agitation without fever All patients% N % N % N

Infection 86.9 119 13.0 24 44.5 143Tooth-eruption problems 8.0 11 22.3 41 16.2 52General agitation 2.9 4 34.2 63 20.9 67Abdominal pain 0.7 1 17.4 32 10.3 33Other 1.5 2 13.0 24 8.1 26Total 100.0 137 100.0 184 100.0 321

Tabl

e 2

SEVERITY, NATURE, AND DURATION OF THE ILLNESS AT THE START OF THE TREATMENT, STRATIFIED ACCORDING TO THE BASIC SYMPTOMS (DIFFERENCE FROM 100% = MISSING DATA).Criteria Basic symptoms

Agitation with fever Agitation without fever% N % N

Severity of the illness Mild 19.0 26 24.5 45Moderate 66.4 91 57.6 106Severe 9.5 13 16.3 30

Nature of the illness Acute 87.6 120 54.9 101Chronic 4.4 6 15.8 29Relapsing 1.5 2 11.4 21

Duration of illness at the 1-3 days 70.8 97 41.3 76start of the treatment 4-7 days 20.4 28 19.6 36

1-2 weeks 3.6 5 25.5 47> 2 weeks 0.7 1 6.0 11

Tabl

e 3

LENGTH OF TIME TO FIRST GLOBAL IMPROVEMENT IN SYMPTOMS.Time Basic symptoms

Agitation with fever Agitation without fever All patients% N % N % N

After 1st use 5.8 8 14.7 27 10.9 35After 1 day 11.7 16 8.2 15 9.7 31After 2 days 20.4 28 11.4 21 15.3 49After 3 days 24.8 34 16.8 31 20.2 65After 4-7 days 25.5 35 20.7 38 22.7 73After more than 1 week 5.1 7 20.1 37 13.7 44No improvement 1.5 2 0.5 1 0.9 3Treatment discontinued 4.4 6 6.0 11 5.3 17No information 0.7 1 1.6 3 1.2 4Total 100.0 137 100.0 184 100.0 321

Tabl

e 4

OVERALL ASSESSMENT OF THE THERAPEUTIC OUTCOME.Ratings Basic symptoms Adjuvant therapy

Agitation with fever Agitation without fever Yes No All patients% N % N % N % N % N

Very good 62.0 85 44.0 81 50.9 83 52.5 83 51.7 166Good 29.9 41 46.7 40.5 66 38.6 38.6 61 39.6 127Moderate 2.2 3 2.2 4 2.5 4 1.9 3 2.2 7Unsuccessful 1.5 2 4.9 9 1.2 2 5.7 9 3.4 11Worse 0.7 1 1.1 2 1.8 3 0.0 0 0.9 3No information 3.6 5 1.1 2 3.1 5 1.3 2 2.2 7Total 100.0 137 100.0 184 100.0 163 100.0 158 100.0 321

Tabl

e 5

3.5

3

2.5

2

1.5

1

Initialexamination

1stintermediateexamination

2ndintermediateexamination

Finalexamination

All patientsGroup AGroup B

Inte

nsity

Fig 1: Course of the meanintensity of the principalclinical symptoms (allsymptoms, arithmeticmean, stratified accordingto total patient popula-tion): group A (agitationwith fever) and group B(agitation without fever).

Intensity:1 = without symptoms2 = mild3 = moderate4 = severe

3.5

3

2.5

2

1.5

1

Initialexamination

1stintermediateexamination

2ndintermediateexamination

Finalexamination

Sleeping problemsPainRestlessnessFever

Inte

nsity

Fig 2: Course of theintensity of the fourmost commonly men-tioned specific principalclinical symptoms (arithmetic mean,referred to the totalpatient population).

Intensity:1 = without symptoms2 = mild3 = moderate4 = severe

Medic

al SUMMARIES

12

ACUTE OTITIS MEDIA IN CHILDREN: A COMPARISON OF CONVENTIONAL AND HOMEOPATHIC TREATMENT

Pediatricians, GP

K.H. Friese, M.D.; Sigrid Kruse, M.D.; H.Moeller

Biomedical Therapy /Vol. XV/No.4 1997

This prospective study compares conventional and homeopathic

treatment of acute childhood otitis media in five otolaryngological

practices. Group A was initially treated exclusively with homeopathic

single remedies (Aconitum napellus, Apis mellifica, Belladonna,

Capsicum, Chamomilla, Kalium bichromicum, Lachesis, Lycopodium,

Mercurius solubilis, Okoubaka, Pulsatilla, and Silicea), while group B

was treated with nose drops, antibiotics, secretolytics, and/or antipyret-

ics. Factors compared were: otoscopic findings, fever, results of therapy,

intensity and duration of pain, duration of therapy, and frequency of

recurrences. The children accepted into the study ranged in age from

one to eleven years. There were 103 children in Group A, 28 in Group

B. The difference in number is explained by the fact that the

homeopathically-oriented ENT practice involved in this study treats a

great many children, whereas in conventional therapy the first physi-

cian to be consulted about a middle ear inflammation is usually a pedi-

atrician. Median duration of pain was two days in Group A, three days

in Group B. Median duration of treatment was four days in Group A

and ten days in Group B. (Antibiotics are typically prescribed for 8-10

days, while homeopathics can be discontinued sooner if a cure has been

effected.) In Group A, 70.7% of the patients experienced no recur-

rences within one year of treatment; 29.3% had a maximum of three

recurrences. In Group B, 56.6% experienced no recurrences and

43.5% had a maximum of six recurrences. Of the 103 children in

Group A, five were eventually prescribed antibiotics; 98 were com-

pletely cured by the homeopathic treatment. No lasting harmful effects

of therapy were observed in either group.

13

ANTIHOMOTOXIC THERAPY OF RESPIRATORYDISORDERS FROM A PEDIATRIC STANDPOINT

Konrad Werthmann, M.D. Biological Therapy/Vol.XI/No.4 1993

The trachea and the bronchi form an anatomical and func-

tional entity. Passively, they serve for the exchange of res-

piratory gases - and actively, for self-cleansing of the lungs

by transport of secretion from the alveoli to the larynx.

By virtue of its situation, the bronchial tree is susceptible

to the consequences of environmental influences e.g.

pleurorrhea, valvular pneumothorax, atelectasis, and

Echinococcus cysts. By virtue of its anatomy and function,

the bronchial tree is susceptible to exogenous noxae. The

tracheo bronchial system, however, possesses only limited

possibilities as countermeasures against the many and

various toxins acting on it.

Contrary to the situation with adults, disorders of the tracheobronchial system among children are restrict-

ed with respect to variety. They nevertheless play an extremely important role in the entire spectrum of child-

hood diseases: one child in three who visits a physician suffers from a respiratory disease. These disorders

may be broken down into the following approximate schematic representation:

1. Malformations and anomalies

2. Disturbances in gas exchange

Therapies can be broken down into:

a. Antihomotoxic therapy

b. Dietary measures

c. Administration, as developed by Dosch, of neural-therapeutic infiltration of the ganglion stellatum.

The tolerability was reported as excellent or good in almost all of the cases (99%).

In total it can be stated that Galium-Heel is an essential and safe preparation. It is highly effective at helping

to detoxify the organism, especially for patients with chronically recurring complaints.

Medic

al SUMMARIES

Pediatricians,Internists, GP

In You

r PRACTICE

14

PROGRESSION OF THE HEALING CRISIS

BLOOD ⇒ CONNECTIVE TISSUE ⇒ BONE ⇒ ORGAN

The healing crisis happens less often in homoto-

xicology than in classical homeopathy, mainly

because Heel remedies are homeopathic compos-

ites. Compounding several remedies allows for a

broad spectrum medicine that can treat a wide

range of conditions. Combining different attenu-

ations balances the molecular and energetic nature

of the compound, thus influencing the biochemi-

cal and energy pathways of the body for a truly

safe holistic protocol. These same reasons make

Heel remedies easier to administer for the practi-

tioner who is not a homeopath. Unlike classical

homeopathy, homotoxicology does not work

through definite “drug pictures,” but rather by

defusing the toxins.

It is at this level of defusing toxins that composites

may induce the healing crisis, but we must con-

sider it an “antihomotoxic healing crisis,” which,

instead of aggravating symptoms, shifts them. In

simple terms, a reaction phase that starts in the

respiratory system may shift to the lymphatic sys-

tem: a typical path of detoxification.

The healing crisis should be considered as a “good

response”. Patients should be briefed on the possi-

ble occurrence of the healing crisis with any

homeopathic treatment. Some practitioners

choose to avoid talking to their patients about this

possibility. Although this is a personal choice,

avoiding the issue can deter the patient from

homeopathy and sap their confidence in the

physician.

Compared to orthodox treatment with prescrip-

tion drugs, which have side effects that are not

beneficial and are not indicative that the medica-

tion is working, the healing crisis is a mild incon-

venience. Explaining the process and meaning of

the healing crisis can raise the esteem patients have

towards the physician and comfort him or her

if exacerbation occurs; possibly saving you a

phone call ! Learning how to use the table of

Homotoxicosis will guide you through your

patient’s healing process. Whether the healing

crisis occurs or not, it is an issue to be addressed

in your practice.

THE HEALING CRISISThe healing crisis is a normal consequence of

homeopathic therapy. It is the climax of healing,

which is manifested as an exacerbation of symp-

toms occuring between the second and fifth day of

treatment. Although this phenomenon is uncom-

fortable for the patient, it is an indication that the

protocol is working and that the physician is on

target.

As a general rule, you can expect the healing crisis

to occur in humoral and in immune related

responses; such as, allergies, hormonal conditions,

and physiological conditions dependent on

the binding of immune components such as

osteoblasts in the treatment of osteoporosis with

Osteel.

You can expect the exacerbation of symptoms to

last between two and five days. Conditions invol-

ving the simpler cellular structures would be

aggravated for a shorter period of time than those

involving the more complex organs.

1 to 5 DAYS

15

Pediatr

icCOLUMN

RESEARCH

CHAMOMILLA RECUTILA D1 (Chamomile)Restless conditions, insomnia, catarrh conditions, glandular swellings, colic, otitis.

ATROPA BELLADONNA D2 (Deadly nightshade)Febrile infections with inflammation of organs, cerebral irritation and inflammation of meninges.

SOLARUM DULCAMARA D4 (Bittersweet)Eustachian and middle ear conditions.

PLANTAGO MAJOR D3 (Plantain)Otitis media and pain in head region, enuresisnocturna, toothache, skin rashes, diarrhea.

PULSATILLA PRATENSIS D2 (Wild flower)Inflammation of middle ear and organs, measles,mumps, headache, sleeplessness, nervous distur-bances, mood swings.

CALCAREA CARBONICA D8 (Inner white part of oyster shell)Tendency towards colds and flu, inflammation ofrespiratory passages, infantile facial eczema, glan-dular swellings, inflammation of the mucosa.

POSSIBLE CAUSES OF AGITATION WHEN PRESCRIBING VIBURCOL COULD BE USEFUL• Viral infections (especially during the incubation phase)

• Otitis

• Pharyngitis

• Infections

• Food allergies or intolerances

• Teething

VIBURCOL is a homeopathic compoundmedicine that can replace aspirin-typedrugs, nonsteroidal anti-inflammatorydrugs, antipyretic drugs and analgesics.

in ORTHODOX MEDICINEVIBURCOL

USE OF VIBURCOLVIBURCOL was developed for the treatment of agitation and restlessness in children.

Disturbances such as sleeplessness, crying, tantrums, etc. are attributed to many physiological conditions such

as otitis and odontoneuralgia. Emotional states such as problems with siblings or classmates, family strife etc..

can also provoke agitation and tantrums, especially in young children who are unable to express stress.

Available in certain countries under a new monodose format!

In a drug monitoring study with 321 children, agedbetween 11 days and 12 years, the following conditionswere treated with VIBURCOL with “good” to “verygood” results in over 90% of the cases:

• respiratory infections • stomach cramps

• flu • restlessness

• otitis media • sleeping disorders

• enteral infections • hyperactivity

• urinary tract infections • dermatological irritations

• teething problems

More than 10% of the study patients exhibited globalimprovement after just one dose of VIBURCOL.Within one week, approximately 80% of the childrenexhibited improvement.

GENERAL PROTOCOL WITH VIBURCOL:

For children over six months of age:

Acute condition (ex. Flu): 1 suppository every fourhours until alleviation of symptoms. Then one suppository 2-3 times a day.

For infants up to six months of age: Insert one suppository (maximum of twice a day).

COMMENTS:

It is important to note that VIBURCOL does notreduce fever dramatically, rather, VIBURCOL allowsfor the gradual alleviation of the underlying condi-tion, supporting soothing of symptoms and healingthrough the body’s own defense mechanism.

PHARMACOLOGICAL NATURE OFINDIVIDUAL CONSTITUENTS:

BREATHE EASIER WITH…

Euphorbium compositum®

Nasal spray

A SAFE AND LONG TERM SOLUTION WITHOUT ANY SIDEEFFECTS TO HELP YOU BREATHE EASIER…

To obtain more information, contact the Heel distributor nearest youand breathe easier with Euphorbium Compositum!

For the safe and natural relief of:

• Chronic nasal discharge • Seasonal rhinitis• Sinusitis• Dry nasal membranes

Euphorbium compositum is the only natural nasalspray to possess an anti-viral action. Hence, itinhibits the propagation of most viruses that areresponsible for the cold and flu. It is safe and efficient for children as well as adults.

“Euphorbium comp. is ideal

for children and women

who are pregnant or

breast feeding!”

®